Spero Therapeutics Files 8-K

Ticker: SPRO · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1701108

Spero Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySpero Therapeutics, Inc. (SPRO)
Form Type8-K
Filed DateAug 5, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, operations, regulation-fd

TL;DR

Spero Therapeutics dropped an 8-K on Aug 5th covering financials and operations.

AI Summary

Spero Therapeutics, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations, financial condition, and providing Regulation FD disclosures. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, Massachusetts.

Why It Matters

This 8-K filing provides crucial updates on Spero Therapeutics' financial status and operational results, which are important for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report detailing financial information and operational results, which typically carries a low inherent risk.

Key Players & Entities

  • Spero Therapeutics, Inc. (company) — Registrant
  • August 5, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Cambridge, Massachusetts (location) — Address of principal executive offices
  • 02139 (zip_code) — Zip code of principal executive offices
  • (857) 242 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing by Spero Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report on Spero Therapeutics, Inc.'s results of operations and financial condition, provide Regulation FD disclosures, and include financial statements and exhibits.

On what date was this 8-K filing reported as the earliest event?

The earliest event reported in this 8-K filing was on August 5, 2024.

In which state is Spero Therapeutics, Inc. incorporated?

Spero Therapeutics, Inc. is incorporated in Delaware.

What is the address of Spero Therapeutics, Inc.'s principal executive offices?

The address of Spero Therapeutics, Inc.'s principal executive offices is 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts, 02139.

What is the telephone number provided for Spero Therapeutics, Inc.?

The telephone number provided for Spero Therapeutics, Inc. is (857) 242.

Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-08-05 16:13:08

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Spero Therapeutics, Inc. on August 5, 2024 99.2 Corporate Investor Presentation of Spero Therapeutics, Inc. as of August 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 5, 2024 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Chief Financial Officer, Chief Business Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.